Gliptins the focus of type 2 diabetes marketing and pricing activity in India

16 July 2015

Gliptins, oral medicines that can reduce the blood sugar levels in type 2 diabetes, are all the rage in India. With the country hosting over 67 million diabetes patients, type 2 diabetes mellitus is also gaining epidemic proportions, reports The Pharma Letter’s India correspondent.

Even as the Delhi High Court restrained Glenmark Pharmaceuticals from manufacturing, marketing or selling its anti diabetes drugs Zita and Zita-Met, stating it had prima facie infringed the patent of US drug major Merck & Co, Glenmark is readying to introduce Teneligliptin in the Indian market.

Set to lower treatment costs by around 60%, the drug is expected to bring about savings of over around $158 per year for diabetic patients. Glenmark has already bagged the regulatory approval for Teneligliptin, and is set to price it at $115 for a year's course, compared to $260 for a year's course of other pharmaceutical companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >